BioMed X Innovation Center, a unique venue for influential, emerging scientists from across the globe to come together to work on groundbreaking pre-clinical studies in the fields of biomedicine, molecular biology, cell biology and bioinformatics, has partnered with pharmaceutical company Boehringer Ingelheim to create a research group focused on discovering potential therapeutics for chronic obstructive pulmonary disease (COPD).
Previous studies have shown the impactful role epigenetic regulators play in driving COPD progression, and that advancing therapeutics formulated for modulation, translation and modification of these regulators can help reduce inflammatory responses and tissue damage, and potentially put a stop to disease progression. It is important to start COPD treatment as early as possible, as it is a progressive disease that can severely limit effective breathing and reduce quality of life.
BioMed X is calling on all interested early career scientists from the world’s top academic institutions to submit their original project proposals, with a special focus on epigenetics and COPD. The newly partnered companies will be selecting the best proposals and life science researchers to become members of the new COPD research group, to work in BioMed X’s innovation lab in Heidelberg, wherein they will receive a generous funding package, entrepreneurial education, and mentorship. The lab is located in side the University of Heidelberg’s life science campus, specially designed to be conducive for out-of-the-box thinking and innovative work. Those selected from this project plan competition will have a unique opportunity to harness epigenetic science to find new solutions for COPD.
[adrotate group=”3″]
BioMed X will be spearheading the recruitment for the COPD research group, activities necessary in operating the innovation lab, providing the winners entrepreneurial education and access to the local scientific community and research facilities. The financial details of the signed agreement between BioMed X and Boehringer were not disclosed.
“We welcome Boehringer Ingelheim as additional pharmaceutical partner to our Innovation Center”, said Christian Tidona, the founder and Managing Director of BioMed X. “This is a major milestone in our endeavor to bridge the translational gap between academia and the pharmaceutical industry.”